Dr. Jesus Anampa is an Associate Professor of Medicine in the Department of Medical Oncology at Albert Einstein College of Medicine/ Montefiore Medical Center. Dr. Anampa is the Clinical Research Leader for Breast Oncology at Montefiore Medical Center and The Phase I Liaison for Breast Oncology.

A native of Peru, Dr. Anampa finished medical school at Universidad Peruana Cayetano Heredia in Lima, Peru, and successfully finished Internal Medicine Residency at Rochester General Hospital in Rochester, NY. Dr. Anampa initially joined Albert Einstein College of Medicine/Montefiore Medical Center to complete his fellowship in hematology/oncology and then joined our medical oncology faculty team at AECOM/MMC. In 2018, he obtained a Master’s of Science degree “with distinction” in clinical research from Albert Einstein College of Medicine. Dr. Anampa is a practicing physician who specializes in breast medical oncology and clinical & translational cancer research. 

Tumor MicroEnvironment of Metastasis

Dr. Anampa is currently working with the tumor microenvironment (TME) program at Albert Einstein College of Medicine, which is a nationwide well-recognized program, lead by Dr. John Condeelis, evaluating new mechanisms of cancer intravasation and dissemination. Dr. Anampa plays an important role in translating bench-to-bedside and bedside-to-bench research in our TME program, and currently, he is working on the Tumor microenvironment of metastasis (TMEM) and its significance as a biomarker in breast cancer. Dr. Anampa is the principal investigator of a novel phase I trial targeting the tumor microenvironment to prevent metastasis. In addition, Dr. Anampa is leading a clinical trial to validate a novel imaging technique to identify metastasis doorways (TMEM) in vivo using MRI in patients with breast cancer.

https://clinicaltrials.gov/ct2/show/NCT03694756

https://clinicaltrials.gov/ct2/show/NCT02824575

Breast Cancer and Obesity

Dr. Anampa is working with the diabetes center at Albert Einstein to identify pathways associated with obesity and breast cancer. Preclinical studies at our institution have demonstrated that the CDK4/6-Rb pathway is affected in diet-induced obesity in mouse models. Dr. Anampa is leading a clinical trial that assesses the effect of CDK 4/6 inhibitors on body composition in patients with metastatic breast cancer.

https://clinicaltrials.gov/ct2/show/NCT03697577

Clinical/Translational Research Leadership

Dr. Anampa is The Clinical Research Leader for Breast Oncology at Montefiore Medical Center/AECOM and he serves as local principal investigator for several Phase I, II, and III trials. In addition, Dr. Anampa is also a member of the Protocol Review and monitoring committee at Montefiore Medical Center/AECOM.

Dr. Anampa serves as the Montefiore Principal Investigator for the Translational Breast Cancer Research symposium (TBCRC) and the (I-Spy2)

Dr. Anampa is a native Spanish-speaker and has an innate passion for breast cancer research, with an ultimate goal to expand breast cancer therapeutic options and improve breast cancer outcomes. Dr. Anampa is also interested in breast cancer research among minorities and is always eager to participate in community activities related to breast cancer.

During his free time, Dr. Anampa enjoys mountain biking and soccer.